Head-To-Head Survey: Artemis Therapeutics (ATMS) and Advanced Emissions Solutions (ADES)
Artemis Therapeutics (OTCMKTS:ATMS) and Advanced Emissions Solutions (NASDAQ:ADES) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.
Valuation and Earnings
This table compares Artemis Therapeutics and Advanced Emissions Solutions’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Artemis Therapeutics||N/A||N/A||-$1.14 million||N/A||N/A|
|Advanced Emissions Solutions||$35.69 million||6.04||$27.87 million||$1.56||6.94|
Advanced Emissions Solutions pays an annual dividend of $1.00 per share and has a dividend yield of 9.2%. Artemis Therapeutics does not pay a dividend. Advanced Emissions Solutions pays out 64.1% of its earnings in the form of a dividend.
Volatility & Risk
Artemis Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Advanced Emissions Solutions has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500.
This table compares Artemis Therapeutics and Advanced Emissions Solutions’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Advanced Emissions Solutions||255.65%||53.06%||49.47%|
Institutional & Insider Ownership
73.7% of Advanced Emissions Solutions shares are owned by institutional investors. 7.5% of Artemis Therapeutics shares are owned by insiders. Comparatively, 10.6% of Advanced Emissions Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and target prices for Artemis Therapeutics and Advanced Emissions Solutions, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Advanced Emissions Solutions||0||0||1||0||3.00|
Advanced Emissions Solutions has a consensus price target of $18.00, indicating a potential upside of 66.20%. Given Advanced Emissions Solutions’ higher probable upside, analysts clearly believe Advanced Emissions Solutions is more favorable than Artemis Therapeutics.
Advanced Emissions Solutions beats Artemis Therapeutics on 11 of the 12 factors compared between the two stocks.
Artemis Therapeutics Company Profile
Artemis Therapeutics Inc., a biopharmaceutical company, engages in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company's lead product candidate is Artemisone, an orally-administered 10-alpha-amino artemisinin derivative with antiviral and antiparasitic properties. It focuses on advancing Artemisone as an antiparasitic treatment for patients infected with Plasmodium falciparum; and as an antiviral agent to address unmet clinical needs in immunocompromised patients infected with human cytomegalovirus and other viral or infectious diseases. The company has license agreement with Hadasit Medical Research Services and Development Ltd., Hadassah Medical Organization, and Hong Kong University of Science and Technology R and D Corporation Limited for the development of Artemisone. Artemis Therapeutics Inc. was incorporated in 1997 and is based in New York, New York. Artemis Therapeutics Inc. is a subsidiary of Tonak Ltd.
Advanced Emissions Solutions Company Profile
ADA-ES, Inc. (ADA) develops, offers, and implements environmental technologies and provides equipment and specialty chemicals that enable coal-fueled power plants to meet emissions regulations by enhancing existing air pollution control equipment. ADA’s wholly owned subsidiaries include Advanced Emissions Solutions, Inc., ADA Intellectual Property, LLC and ADA Environmental Solutions, LLC. ADA holds a 42.5% controlling interest in Clean Coal Solutions, LLC. It operates in three segments: Refined coal (RC), Emission control (EC) and CO2 capture (CC). ADA is a supplier of mercury control equipment and services to the EC markets. It also offers dry sorbent injection systems (DSI) to control SO2 and acid gases. Products, such as the Company’s CyCleanTM and M-45TM technologies, its pre-combustion coal treatment processes that provide electric power generators mercury emission control. In September 2012, it acquired the assets of Bulk Conveyor Specialist Inc. and Bulk Conveyor Services, Inc.
Receive News & Ratings for Artemis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artemis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.